30 results about "Blood derivatives" patented technology

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

The present invention is directed to metal-phthalocyanines of general formula (I) to the corresponding conjugates, the processes for their preparation and use in the photodynamic therapy of microbial infections (viral, bacterial and mycotic), tumor, pre-cancerous and proliferative pathologies and / or in the diagnosis, as well as for blood and blood derivatives sterilization

The present invention is directed to metal-phthalocyanines of general formula (I) to the corresponding conjugates, the processes for their preparation and use in the photodynamic therapy of microbial infections (viral, bacterial and mycotic), tumor, pre-cancerous and proliferative pathologies and / or in the diagnosis, as well as for blood and blood derivatives sterilization.

The invention relates to a method for the determination of a cancer diagnostic / therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein / peptide biomarkers and drug-targets based on the measurement of protein / peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein / peptide biomarkers those which show a pronounced differential behavior between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein / peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein / peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behavior between healthy and cancerous sample proteomes; (c) validation of the candidate protein / peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and / or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein / peptide biomarkers those which show a mass-spectrometrically measurable and / or antibody-based assay detectable differential behavior between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein / peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself.

A collecting device for fluids for medical use may include a rigid container internally defining a first chamber having a fixed volume, an auxiliary container having a deformable portion defining internally thereof a second chamber having a variable volume as a function of a deformable portion thereof, a passage able to set the first and the second chamber in fluid communication, an inlet port connected to at least one of the containers, and an outlet port connected to at least one of the containers, as well as a bypass line for bypassing the device.

A hermetically-sealed plastics container for blood derivative products is provided. The container may have an internal surface and an external surface, characterized in that it comprises an RFID inlay between the internal surface and the external surface.

The present invention provides an enyzmatic cycling assay for assessing the amount of homocysteine and / or cystathionine in a solution such as blood, blood derivatives, or urine. The assay comprises the steps of contacting the solution containing homocysteine and / or cystathionine to form a reaction mixture, with CBS, or a derivative thereof, L-serine, and CBL, or a derivative thereof, for a time period sufficient to catalyze the cyclical conversion of homocysteine form to cystathionine and the reconversion of cystathionine to homocysteine with the production of pyruvate and ammonia; determiningthe amount of homocysteine and / or ammonia present in the reaction mixture; and determining the amount of homocysteine and / or cystathionine present in the solution based on the amount of pyruvate and / or ammonia formed. Expression vectors and isolation procedures for CBS, or derivatives thereof, and CBI, or derivatives thereof, are also provided as well as test kits for carrying out the assay. In preferred embodiments, the assays can be conducted in 15 minutes or less, with a minimum of enzyme usage.

A filter unit for blood and blood derivatives comprises a body defined by two injection-moulded half-shells of thermoplastic polymer material, there being present between said half-shells a cavity containing a filtering element having two opposing flat faces, an inlet opening and an outlet opening made on the opposing outer surfaces of said body communicating with said cavity. Each of said half-shells comprises a projecting perimetral flange, the flanges of the overlapping half-shells being welded together to form a flange of the body of the filter unit and connect the two half-shells together, the filtering element being wholly contained within the cavity of such body and pressed by shelves projecting into such cavity from each half-shell in the vicinity of its perimetral border and on the two opposing faces, said shelves retaining said filtering element in a stable position within cavity, said thermoplastic polymer material being yielding and semi-rigid.

Provided is an infusion system including: a liquid container that accommodates a blood derivative; a heating device that heats the blood derivative; an air bubble removal chamber that removes air bubbles in the blood derivative; a first flow path that connects the liquid container and the heating device to each other; a second flow path that connects the heating device and the air bubble removal chamber to each other; a third flow path that connects the air bubble removal chamber and an infusion unit to each other; a fourth flow path that connects the air bubble removal chamber and the liquid container to each other; a first pump provided in the first flow path; and a second pump provided in the third flow path. The heating device has a heating flow path where the blood derivative flows and a heat supply body that contacts the heating flow path.

A collecting device for fluids for medical use may include a rigid container internally defining a first chamber having a fixed volume, an auxiliary container having a deformable portion defining internally thereof a second chamber having a variable volume as a function of a deformable portion thereof, a passage able to set the first and the second chamber in fluid communication, an inlet port connected to at least one of the containers, and an outlet port connected to at least one of the containers, as well as a bypass line for bypassing the device.